ClinicalTrials.gg
CompletedNCT01455012ENCOREUpdated Jul 26, 2013Results posted

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome

A Phase 4 interventional study of Rotigotine and Placebo in Restless Legs Syndrome, sponsored by UCB BIOSCIENCES GmbH. Completed at 6 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-26.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
11th of 19
81 · median 130
Started
2011
with 2 others
Phase 4
3 of 19
none open now
Registered
10th of 19
by date
Lead sponsor
2 of 19
UCB BIOSCIENCES GmbH

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 11th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 4, and was the 10th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

Periodic Limb Movements (PLMs) during sleep in patients with Restless Legs Syndrome (RLS) have been shown to be associated with elevations in Blood Pressure (BP). Rotigotine has been shown to effectively reduce the incidence of PLMs in patients with RLS. The current study aims to demonstrate that treatment with Rotigotine could help reduce the number of nocturnal BP elevations associated with PLMs in patients with RLS.

03

Conditions studied

  • Restless Legs Syndrome

Keywords

  • Rotigotine
  • Neupro
  • RLS
  • Cardiovascular Risk
  • Nocturnal Blood Pressure
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is informed and given ample time and opportunity to think about her/his participation and give her/his written
  • Subject understands the nature of the study and is willing and able to comply with the study requirements. Subject is willing to accept that he/she might be treated with placebo during the Treatment Period
  • Subject is able to apply/remove the study patch correctly
  • Subject is male or female, and is ≥18 and ≤75 years of age
  • Subject meets the diagnosis of idiopathic Restless Legs Syndrome (RLS) based on the 4 essential clinical features according to the International Restless Legs Syndrome Study Group (Allen et al,2003): 1. An urge to move legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (The urge to move can be present without uncomfortable sensations. Arms or other body parts can also be affected) 2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying or sitting 3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues 4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present)
  • Subject has a score of ≥11 on the RLS-Diagnostic Index (RLS-DI) (Benes and Kohnen, 2009)
  • Subject has an initial response to previous dopaminergic treatment for RLS or has no previous dopaminergic treatment (ie, de novo)
  • The subject's (BMI) is ≥18 kg/m\^2 and ≤35 kg/m\^2
  • At Baseline subject has a score of ≥15 on the IRLS (indicating moderate to severe RLS)
  • At Baseline subject has a score of ≥4 points on the CGI Item 1 assessment (indicating moderately ill)
  • At Baseline subject has a score of ≥15 PLM/h on the Periodic Limb Movements Index (PLMI) based on polysomnography (PSG) (recorded during the second night) as assessed by the investigator
  • Subjects are on a concomitant dose of antihypertensives that is at a stable dose for at least 4 weeks prior to Baseline and hypertension is reasonably controlled while the subject agrees to continue at this dose for the duration of the study, or subject has not received concomitant treatment with antihypertensives for at least 4 weeks prior to Baseline and does not intend to start such use during the study

Exclusion criteria

Exclusion Criteria:

  • Subject has RLS due to renal insufficiency (uremia), iron deficiency anemia, or rheumatoid arthritis
  • Subject has RLS associated with previous or concomitant therapy with dopamine D2 receptor antagonists, butyrophenones, metoclopramide, atypical antipsychotics (eg, olanzapine), tri- and tetra-cyclic antidepressants, mianserine, or lithium or H2-blockers (eg, cimetidine), or due to withdrawal from drugs such as anticonvulsants, benzodiazepines, barbiturates, and other hypnotics
  • Subject has a history of sleep disturbances, such as sleep apnea syndrome (including obstructive sleep apnea), narcolepsy, sleep attacks/sudden onset of sleep, or myoclonus epilepsy either observed during PSG (local PSG evaluations) or evidenced by subject history
  • Subject has uncontrolled hypertension according to the judgment of the investigator
  • Subject has additional concomitant diseases, such as attention deficit hyperactivity disorder, polyneuropathy, akathisia, claudication, varicosis, muscle fasciculation, painful legs and moving toes, or radiculopathy
  • Subject has other central nervous system diseases, such as Parkinson's disease, dementia, progressive supranuclear paresis, multisystem atrophy, Huntington's chorea, amyotrophic lateral sclerosis, or Alzheimer's disease.
  • Subject has a prior history of psychotic episodes
  • Subject has a history of chronic alcohol or drug abuse within the previous 12 months
  • Subject has any medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the subject's ability to participate in this study
  • Subject has clinically relevant cardiac dysfunction and/or arrhythmias (eg, suspected conduction system dysregulations, second or third degree atrioventricular block, complete left or right bundle branch block, sick sinus syndrome, Class III or IV congestive heart failure, or had a myocardial infarction within 12 months prior to Screening [Visit 1])
  • Subject has clinically relevant venous or arterial peripheral vascular disease
  • Subject has a malignant neoplastic disease requiring therapy within 12 months prior to Screening (Visit 1)
  • Subject is currently receiving treatment with any of the following drug classes: neuroleptics, hypnotics, antidepressants, anxiolytic drugs, anticonvulsive therapy, budipine, dopamine antagonist antiemetics (except domperidone), opioids, benzodiazepines, monoamine oxidase (MAO) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, sedative antihistamines, psychostimulates, or amphetamines. If subject has received such therapy, a of at least 7 days prior to Baseline (Visit 2) is required before starting treatment in this study
  • Subject is pregnant, nursing, or is a woman of who is not surgically sterile, 2 years , or does not consistently use 2 combined effective methods of , including at least 1 barrier method, unless sexually abstinent
  • Subject is a shift worker or performs other continuous non-disease-related life conditions which do not allow regular sleep at night
  • At Screening Visit or Baseline Visit subject has symptomatic orthostatic hypotension
  • Subject is treated with dopamine agonists within a period of 14 days prior to Baseline or L-dopa within 7 days prior to Baseline
  • Subject has a medical history indicating intolerability to prior dopaminergic therapy (if pretreated)
  • Subject has received previous treatment with Rotigotine
  • Subject has participated in another study of an drug or device within the 28 days prior to Visit 2 (Baseline) or is currently participating in another study of an investigational drug
  • Subject has a known to any of the components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis
  • Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening (Visit 1)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.

  • DrugPlacebo

    Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Number of Elevations of Systolic Blood Pressure (BP) During the Night That Are Associated With Periodic Limb Movements (PLMs) at the End of the 4-week Maintenance Period

    Polysomnography (PSG) recordings, including the assessment of continuous Blood Pressure and 12-lead Electrocardiogram (ECG), were obtained on 2 consecutive nights prior to Baseline Visit and prior to End of Maintenance Period (Visit 7) for up to 8 hours per night. Readings from the first night of the PSG were only used for analysis if the PSG from the second night was determined to be not valid for evaluation. Influence of Periodic Limb Movements (PLMs) on sleep is reflected in the Periodic Limb Movement-Related Arousal Index (PLMAI). Arousal is defined as sudden change in the EEG activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. Sleep stages and time spent in each sleep stage were determined from Electroencephalogram (EEG) readings. A negative value in Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

Secondary outcomes

  1. Change From Baseline in the Total Number of Elevations of Systolic Blood Pressure (BP) During the Night at the End of the 4-week Maintenance Period

    Polysomnography (PSG) recordings, including the assessment of continuous Blood Pressure and 12-lead Electrocardiogram (ECG), were obtained on 2 consecutive nights prior to Baseline Visit and prior to End of Maintenance Period (Visit 7) for up to 8 hours per night. Readings from the first night of the PSG were only used for analysis if the PSG from the second night was determined to be not valid for evaluation. Influence of Periodic Limb Movements (PLMs) on sleep is reflected in the Periodic Limb Movement-Related Arousal Index (PLMAI). Arousal is defined as sudden change in the EEG activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. Sleep stages and time spent in each sleep stage were determined from Electroencephalogram (EEG) readings. A negative value in Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  2. Change From Baseline in the Periodic Limb Movements Index (PLMI) at the End of the 4-week Maintenance Period

    The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). A negative value in PLMI Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  3. Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at the End of the 4-week Maintenance Period

    The IRLS is a subject-based scale that consists of 10 items to evaluate the severity of major RLS symptoms and the impact of the disease on subjects' daytime functioning. Each of the 10 items is measured on a scale that ranges from 0 (not present) to 4 (severe). A sum score between 0 (no RLS symptoms present at all) and 40 (maximum severity in all symptoms) across all 10 items was calculated. A negative value in IRLS Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  4. Change From Baseline in Restless Legs Syndrome-Quality of Life (RLS-QoL) at the End of the 4-week Maintenance Period

    The RLS-QoL is a disease-specific instrument for the evaluation of Quality of life. It consists of 12 items and the overall sum score is calculated from all 12 items and measured on a scale that ranges from 0 (lowest Quality of life) to 60 (highest level of Quality of life). A negative value in RLS-QoL Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  5. Clinical Global Impressions (CGI) Item 2 (Change of Condition) at the End of the 4-week Maintenance Period

    The CGI Item 2 score measures any change in severity of RLS from Baseline on a 7-point scale consisting of the following categories: * 1- Very much improved * 2- Much improved * 3- Minimally improved * 4- No change * 5- Minimally worse * 6- Much worse * 7- Very much worse

    Time frame: At the end of the 4-week Maintenance Period

  6. Clinical Global Impressions (CGI) Item 1 (Severity of Illness) at the End of the 4-week Maintenance Period

    The CGI Item 1 score measures the severity of illness on a 7-point scale consisting of the following categories: * 1- Normal, not ill at all * 2- Borderline ill * 3- Mildly ill * 4- Moderately ill * 5- Markedly ill * 6- Severely ill * 7- Among the most extremely ill subjects

    Time frame: At the end of the 4-week Maintenance Period

  7. Clinical Global Impressions (CGI) Item 3 (Therapeutic Efficacy) at the End of the 4-week Maintenance Period

    The CGI Item 3 score measures the therapeutic efficacy on a 4-point scale consisting of the following categories: * 1- Very good * 2- Moderate * 3- Slight * 4- Unchanged or worse

    Time frame: At the end of the 4-week Maintenance Period

  8. Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 1 at the End of the 4-week Maintenance Period

    The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 1 measures subject's satisfaction with sleep on a 11-point scale that ranges between 0 (completely satisfied) to 10 (completely dissatisfied). The ratings are given by the subjects. A negative value in RLS-6 Item 6 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  9. Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 2 at the End of the 4-week Maintenance Period

    The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 2 measures the severity of RLS at time falling asleep on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 2 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  10. Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 3 at the End of the 4-week Maintenance Period

    The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 3 measures the severity of RLS during the night on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 3 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  11. Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 4 at the End of the 4-week Maintenance Period

    The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 4 measures the severity of RLS during day rest on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 4 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  12. Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 5 at the End of the 4-week Maintenance Period

    The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 5 measures the severity of RLS during day not rest on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 5 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

  13. Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 6 at the End of the 4-week Maintenance Period

    The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 6 measures subject's tiredness or sleepiness during the day on a 11-point scale that ranges between 0 (not at all) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 6 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline to the end of the 4-week Maintenance Period

07

Results

Posted Jul 18, 2013

Participant flow

This study started to enroll subjects in September 2011 in order to end up with 9 German centers with enrolled subjects.

Participant flow — Overall Study
MilestonePlaceboRotigotine
Started4140
Completed3036
Not completed114
Withdrew: Adverse event02
Withdrew: Lack of efficacy61
Withdrew: Withdrawal by subject31
Withdrew: Unknown reason20

Outcome measures

PrimaryChange From Baseline in the Number of Elevations of Systolic Blood Pressure (BP) During the Night That Are Associated With Periodic Limb Movements (PLMs) at the End of the 4-week Maintenance Period

Polysomnography (PSG) recordings, including the assessment of continuous Blood Pressure and 12-lead Electrocardiogram (ECG), were obtained on 2 consecutive nights prior to Baseline Visit and prior to End of Maintenance Period (Visit 7) for up to 8 hours per night. Readings from the first night of the PSG were only used for analysis if the PSG from the second night was determined to be not valid for evaluation. Influence of Periodic Limb Movements (PLMs) on sleep is reflected in the Periodic Limb Movement-Related Arousal Index (PLMAI). Arousal is defined as sudden change in the EEG activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. Sleep stages and time spent in each sleep stage were determined from Electroencephalogram (EEG) readings. A negative value in Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Least squares mean · Nocturnal Elevations of Systolic BP
Change From Baseline in the Number of Elevations of Systolic Blood Pressure (BP) During the Night That Are Associated With Periodic Limb Movements (PLMs) at the End of the 4-week Maintenance Period
Nocturnal Elevations of Systolic BPPlaceboRotigotine
Change From Baseline in the Number of Elevations of Systolic Blood Pressure (BP) During the Night That Are Associated With Periodic Limb Movements (PLMs) at the End of the 4-week Maintenance Period-79.61 ± 189.3-239.95 ± 237.1
Statistical analysis
  • Placebo vs Rotigotine · ANCOVA · p = <0.0001 (The analysis of this primary efficacy variable was performed using a two-sided alpha level of 5 %.) · Mean difference (final values): -160.34 · 95% CI -213.23 to -107.45The treatment effect was estimated on the basis of the Least Square Mean (LSM) of the difference as well as on the 95 % Confidence Interval and the p-value for that difference. Difference to Placebo was calculated as Rotigotine-Placebo.
SecondaryChange From Baseline in the Total Number of Elevations of Systolic Blood Pressure (BP) During the Night at the End of the 4-week Maintenance Period

Polysomnography (PSG) recordings, including the assessment of continuous Blood Pressure and 12-lead Electrocardiogram (ECG), were obtained on 2 consecutive nights prior to Baseline Visit and prior to End of Maintenance Period (Visit 7) for up to 8 hours per night. Readings from the first night of the PSG were only used for analysis if the PSG from the second night was determined to be not valid for evaluation. Influence of Periodic Limb Movements (PLMs) on sleep is reflected in the Periodic Limb Movement-Related Arousal Index (PLMAI). Arousal is defined as sudden change in the EEG activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. Sleep stages and time spent in each sleep stage were determined from Electroencephalogram (EEG) readings. A negative value in Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · Nocturnal Elevations of Systolic BP
Change From Baseline in the Total Number of Elevations of Systolic Blood Pressure (BP) During the Night at the End of the 4-week Maintenance Period
Nocturnal Elevations of Systolic BPPlaceboRotigotine
Change From Baseline in the Total Number of Elevations of Systolic Blood Pressure (BP) During the Night at the End of the 4-week Maintenance Period-34.3 ± 243.4-199.8 ± 262.8
SecondaryChange From Baseline in the Periodic Limb Movements Index (PLMI) at the End of the 4-week Maintenance Period

The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). A negative value in PLMI Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · Periodic Limb Movements/hour
Change From Baseline in the Periodic Limb Movements Index (PLMI) at the End of the 4-week Maintenance Period
Periodic Limb Movements/hourPlaceboRotigotine
Change From Baseline in the Periodic Limb Movements Index (PLMI) at the End of the 4-week Maintenance Period-15.2 ± 50.3-50.1 ± 44.5
SecondaryChange From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at the End of the 4-week Maintenance Period

The IRLS is a subject-based scale that consists of 10 items to evaluate the severity of major RLS symptoms and the impact of the disease on subjects' daytime functioning. Each of the 10 items is measured on a scale that ranges from 0 (not present) to 4 (severe). A sum score between 0 (no RLS symptoms present at all) and 40 (maximum severity in all symptoms) across all 10 items was calculated. A negative value in IRLS Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at the End of the 4-week Maintenance Period-12.5 ± 9.0-18.5 ± 8.0
SecondaryChange From Baseline in Restless Legs Syndrome-Quality of Life (RLS-QoL) at the End of the 4-week Maintenance Period

The RLS-QoL is a disease-specific instrument for the evaluation of Quality of life. It consists of 12 items and the overall sum score is calculated from all 12 items and measured on a scale that ranges from 0 (lowest Quality of life) to 60 (highest level of Quality of life). A negative value in RLS-QoL Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-Quality of Life (RLS-QoL) at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-Quality of Life (RLS-QoL) at the End of the 4-week Maintenance Period-11.0 ± 11.9-17.8 ± 13.2
SecondaryClinical Global Impressions (CGI) Item 2 (Change of Condition) at the End of the 4-week Maintenance Period

The CGI Item 2 score measures any change in severity of RLS from Baseline on a 7-point scale consisting of the following categories: * 1- Very much improved * 2- Much improved * 3- Minimally improved * 4- No change * 5- Minimally worse * 6- Much worse * 7- Very much worse

Time frame:
At the end of the 4-week Maintenance Period
Reported as:
Number · participants
Clinical Global Impressions (CGI) Item 2 (Change of Condition) at the End of the 4-week Maintenance Period
participantsPlaceboRotigotine
Very much improved926
Much improved97
Minimally improved43
No change61
Minimally worse10
Much worse00
Very much worse00
SecondaryClinical Global Impressions (CGI) Item 1 (Severity of Illness) at the End of the 4-week Maintenance Period

The CGI Item 1 score measures the severity of illness on a 7-point scale consisting of the following categories: * 1- Normal, not ill at all * 2- Borderline ill * 3- Mildly ill * 4- Moderately ill * 5- Markedly ill * 6- Severely ill * 7- Among the most extremely ill subjects

Time frame:
At the end of the 4-week Maintenance Period
Reported as:
Number · participants
Clinical Global Impressions (CGI) Item 1 (Severity of Illness) at the End of the 4-week Maintenance Period
participantsPlaceboRotigotine
Normal, not ill at all26
Borderline ill818
Mildly ill79
Moderately ill82
Markedly ill32
Severely ill10
Among the most extremely ill subjects00
SecondaryClinical Global Impressions (CGI) Item 3 (Therapeutic Efficacy) at the End of the 4-week Maintenance Period

The CGI Item 3 score measures the therapeutic efficacy on a 4-point scale consisting of the following categories: * 1- Very good * 2- Moderate * 3- Slight * 4- Unchanged or worse

Time frame:
At the end of the 4-week Maintenance Period
Reported as:
Number · participants
Clinical Global Impressions (CGI) Item 3 (Therapeutic Efficacy) at the End of the 4-week Maintenance Period
participantsPlaceboRotigotine
Very good1131
Moderate104
Slight31
Unchanged or worse51
SecondaryChange From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 1 at the End of the 4-week Maintenance Period

The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 1 measures subject's satisfaction with sleep on a 11-point scale that ranges between 0 (completely satisfied) to 10 (completely dissatisfied). The ratings are given by the subjects. A negative value in RLS-6 Item 6 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 1 at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 1 at the End of the 4-week Maintenance Period-3.4 ± 3.1-4.1 ± 3.3
SecondaryChange From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 2 at the End of the 4-week Maintenance Period

The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 2 measures the severity of RLS at time falling asleep on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 2 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 2 at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 2 at the End of the 4-week Maintenance Period-3.9 ± 3.3-4.6 ± 3.8
SecondaryChange From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 3 at the End of the 4-week Maintenance Period

The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 3 measures the severity of RLS during the night on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 3 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 3 at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 3 at the End of the 4-week Maintenance Period-3.7 ± 3.5-4.9 ± 3.3
SecondaryChange From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 4 at the End of the 4-week Maintenance Period

The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 4 measures the severity of RLS during day rest on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 4 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 4 at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 4 at the End of the 4-week Maintenance Period-2.7 ± 3.4-2.9 ± 2.9
SecondaryChange From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 5 at the End of the 4-week Maintenance Period

The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 5 measures the severity of RLS during day not rest on a 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 5 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 5 at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 5 at the End of the 4-week Maintenance Period-1.3 ± 1.9-1.3 ± 2.6
SecondaryChange From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 6 at the End of the 4-week Maintenance Period

The RLS-6 consists of 6 items of which four items are designed to assess severity of RLS and two items cover sleep and daytime tiredness. Item 6 measures subject's tiredness or sleepiness during the day on a 11-point scale that ranges between 0 (not at all) to 10 (very severe). The ratings are given by the subjects. A negative value in RLS-6 Item 6 Change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline to the end of the 4-week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 6 at the End of the 4-week Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in Restless Legs Syndrome-6 Rating Scales (RLS-6) Item 6 at the End of the 4-week Maintenance Period-2.5 ± 2.8-3.5 ± 2.8

Adverse events

Collected over Adverse Events were collected up to 16 weeks from Screening Period to the Safety Follow-Up Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/40 (0%)19/40 (47.5%)
Rotigotine—0/40 (0%)23/40 (57.5%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboRotigotine
NauseaGastrointestinal disorders3/409/40
NasopharyngitisInfections and infestations3/407/40
HeadacheNervous system disorders7/407/40
FatigueGeneral disorders6/405/40
SomnolenceNervous system disorders4/404/40
DizzinessNervous system disorders1/404/40
PruritusSkin and subcutaneous tissue disorders1/404/40
DiarrhoeaGastrointestinal disorders3/400/40
Application site pruritusGeneral disorders0/402/40
InfluenzaInfections and infestations2/400/40

Baseline characteristics

Baseline Characteristics refer to the Full Analysis Set (FAS). FAS includes all randomized subjects having both a Baseline and a post-Baseline measurement for the primary efficacy variable.

Age, Categorical
Age, Categorical(Participants)PlaceboRotigotineTotal
<=18 years000
Between 18 and 65 years232649
>=65 years61117
Age Continuous
Age Continuous(years)PlaceboRotigotineTotal
Mean56.0 ± 9.657.9 ± 10.257.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotineTotal
Female182240
Male111526
Region of Enrollment
Region of Enrollment(participants)PlaceboRotigotineTotal
Germany293766
08

Study locations

6 sites
  • Berlin, Germany
  • Kassel, Germany
  • Marburg, Germany
  • München, Germany
  • Münster, Germany
  • Schwerin, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2011
First posted
Oct 19, 2011
Start
Sep 2011
Primary completionActual
May 2012
CompletionActual
Jun 2012
Results first posted
Jul 18, 2013
Last update
Jul 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01455012
Responsible party
Sponsor
First posted
Oct 19, 2011
Start date
Sep 2011
Primary completion
May 2012
Completion
Jun 2012
Results posted
Jul 18, 2013
Last update
Jul 26, 2013

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion